Biopharmaceutical

We help ensure the medicines people take every day are reliably safe and effective, from the common aspirin to the most complex biotherapy. Tests performed using our liquid chromatography-mass spectrometry (LC-MS) instruments ensure the efficacy and safety of these complex, protein-based drugs well before they reach the patient.

  • Enzymatic Digestion: Accelerating Bioseparations with Novel Enzymes

    The Role of Enzymes in LC-MS Analysis of Modern Biotherapeutics  Enzymes are nature’s catalysts, enabling precise and efficient biochemical transformations. In analytical workflows, enzymatic digestion is a cornerstone technique for breaking down complex biomolecules into smaller, more manageable fragments. This process is critical for applications such as peptide mapping in protein characterization and oligonucleotide mapping…

  • FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz 

    The FDA’s October 29, 2025 draft guidance has generated significant attention due to the implications for both developers and patients.  By allowing developers to bypass comparative efficacy studies (CES) when advanced analytics are successful substitutes, the draft guidance avoids one of the most expensive steps, estimated to account for 70% of the total biosimilar development…

  • Charge Detection Mass Spectrometry (CDMS):  Unprecedented Direct Measurement for the Characterization of Mega-Mass Biomolecules 

    Whether you are analyzing adeno-associated viruses (AAVs) or virus-like particles, nucleic acids such as RNAs or lipid nanoparticles (LNPs), proteins, or protein complexes, simple and fit-for-purpose tools with speed, accuracy, and precision are essential for driving biotherapeutic innovations forward. In recent years, scientists have increasingly turned to charge detection mass spectrometry (CDMS). 

  • Bringing it all together – A modern solution for oligonucleotide analysis

    Solving analytical challenges is at the core of our DNA and when it comes to oligonucleotide analysis, we’re at a point now where we can bring together the many advancements we’ve made across the analytical value stream into complete end-to-end workflows that truly deliver best-in-class analytical performance and productivity.

  • Biopharma’s Future: Next-Generation LC-MS Workflows for Peptide MAM

    The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification variants (attributes) creates an interesting analytical challenge for scientists tasked with their characterization and then with monitoring those attributes important…

  • 5 Peptide Bioanalysis Sample Preparation Challenges (and how to overcome them!)

    Scientists that have worked with peptides understand that peptide quantification can be challenging. One of the keys to successful peptide analysis is thorough and selective sample preparation. Sample preparation improves various aspects of chromatography and mass spectrometry analyses by utilizing solid phase extraction (SPE) to chemically separate different analytes and aid in removing the interfering…

  • Mobile Phase Additives for Peptide Characterization

    The characterization of peptides and proteins can be challenging due to issues such as adsorption, varying hydrophobicities, and specificity to name just a few. When analyzing peptides by Liquid Chromatography (LC) and Mass Spectrometry (MS), it’s beneficial to introduce mobile phase additives in order to facilitate ionization and enhance the analyte signal. Additionally, these additives…

  • Sample Prep before LC-MS Quantification of Peptides and Proteins

    Confronting the challenge of sensitivity and sample loss As a relative newcomer to peptide and protein quantification coming from the small molecule world, I have learned that I need to think differently, and more creatively, to meet the challenges of these molecules.  As scientists with assay sensitivity goals, we sometimes have to take extra steps…